miltefosine has been researched along with Disease Models, Animal in 70 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 8.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "A dual drug repurposing/nanotechnological approach was used to develop an alternative oral treatment for schistosomiasis mansoni using miltefosine (MFS), an anticancer alkylphosphocholine, and lipid nanocapsules (LNCs) as oral nanovectors." | 7.83 | Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. ( Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA, 2016) |
| "In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used in a rat model for the topical treatment of Acanthamoeba keratitis." | 7.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 7.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 6.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 5.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "Miltefosine treatment yielded much higher cure scores than propamidine isetionate plus polyhexanide." | 5.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "Miltefosine was fungicidal for C." | 5.33 | Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. ( Ellis, DH; Ganendren, R; Handke, R; Obando, D; Sorrell, TC; Widmer, F; Wright, LC, 2006) |
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 4.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "A dual drug repurposing/nanotechnological approach was used to develop an alternative oral treatment for schistosomiasis mansoni using miltefosine (MFS), an anticancer alkylphosphocholine, and lipid nanocapsules (LNCs) as oral nanovectors." | 3.83 | Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. ( Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA, 2016) |
| "In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used in a rat model for the topical treatment of Acanthamoeba keratitis." | 3.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 3.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| " In this study, a new semi-synthetic berberine analogue, 5,6-didehydro-8,8-diethyl-13-oxodihydroberberine chloride (1), showed nanomolar level potency against in vitro models of leishmaniasis, malaria, and trypanosomiasis as well as activity in an in vivo visceral leishmaniasis model." | 3.77 | Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. ( Anklin, C; Bahar, M; Deng, Y; Doskotch, RW; Drew, ME; Gil, RR; He, S; Kinghorn, AD; Navarro-Vázquez, A; Pandharkar, T; Werbovetz, KA; Zhu, X, 2011) |
| "Patients with liver cirrhosis of different aetiologies are at a risk to develop HCC." | 2.66 | Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. ( Aslanidis, C; Buechler, C, 2020) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 2.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| " One promising pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg in a Leishmania donovani mouse model of visceral leishmaniasis." | 1.62 | Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. ( Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V, 2021) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 1.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "When miltefosine was used as proof-of-concept, spleen weight parasite burden and bioluminescence values decreased significantly." | 1.51 | A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. ( Álvarez-Velilla, R; Balaña-Fouce, R; Fresno, M; Gutiérrez-Corbo, MDC; Pérez-Pertejo, MY; Punzón, C; Reguera, RM, 2019) |
| "Topical treatment for cutaneous leishmaniasis (CL) would be useful for treatment of some forms of the disease." | 1.51 | Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. ( Escobar, P; Mantilla, JC; Neira, LF, 2019) |
| " This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds." | 1.48 | Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. ( Augustyns, K; Baán, A; Caljon, G; Kiekens, F; Maes, L; Matheeussen, A; Salado, IG; Van der Veken, P; Verdeyen, T, 2018) |
| "Tamoxifen was able to hinder the emergence of miltefosine resistance." | 1.43 | Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. ( Coelho, AC; Reimão, JQ; Trinconi, CT; Uliana, SR, 2016) |
| " fumigatus mouse model, adopting a short-term and long-term oral or intraperitoneal dosing regimen." | 1.42 | Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis. ( Bosschaerts, T; Boulet, G; Cos, P; Fortin, A; Maes, L; Paulussen, C, 2015) |
| "Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented." | 1.40 | In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. ( Coelho, AC; Costa, CH; Trinconi, CT; Uliana, SR, 2014) |
| " Oleylphosphocholine (OlPC) is a new orally bioavailable drug of the alkylphosphocholine family with potent antileishmanial activity against a broad range of Leishmania species/strains." | 1.40 | Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis. ( Bosschaerts, T; Caridha, DP; Fortin, A; Grogl, M; Hickman, MR; Hudson, TH; Leed, S; Ngundam, F; Parriott, S; Sena, J, 2014) |
| "Miltefosine treatment yielded much higher cure scores than propamidine isetionate plus polyhexanide." | 1.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "Miltefosine was investigated for its activity against Neospora caninum tachyzoites in vitro, and was shown to inhibit the proliferation of N." | 1.38 | Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites. ( Debache, K; Hemphill, A, 2012) |
| "Combination therapy for the treatment of visceral leishmaniasis has increasingly been advocated as a way to increase treatment efficacy and tolerance, to reduce treatment duration and cost, and to limit the emergence of drug resistance." | 1.37 | Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. ( Gupta, S; Sane, SA; Shakya, N, 2011) |
| "Miltefosine has structural similarity to the PC and sphingomyelin substrates of PlcHR, and we found that it inhibits the cleavage of these choline-containing lipids in vitro." | 1.37 | Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection. ( Allard, JL; Allen, GB; Gross, MJ; Hogan, DA; Leclair, LW; Lundblad, LK; Rajamani, S; Vasil, ML; Wargo, MJ, 2011) |
| " Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice." | 1.36 | Novel arylimidamides for treatment of visceral leishmaniasis. ( Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X, 2010) |
| "Miltefosine was administered orally at 25 mg/kg/day for 10 days, while 10% paromomycin gel was applied topically twice a day for 10 days." | 1.35 | Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. ( Aguiar, MG; Fernandes, AP; Ferreira, LA; Nunan, EA; Nunan, FA; Silva, DL, 2009) |
| "Miltefosine was fungicidal for C." | 1.33 | Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. ( Ellis, DH; Ganendren, R; Handke, R; Obando, D; Sorrell, TC; Widmer, F; Wright, LC, 2006) |
| " Conventional non-compartmental pharmacokinetic analysis and an elaborate three- and four-compartmental model were used for explaining the experimental data." | 1.30 | Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. ( Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.43) | 18.2507 |
| 2000's | 12 (17.14) | 29.6817 |
| 2010's | 46 (65.71) | 24.3611 |
| 2020's | 11 (15.71) | 2.80 |
| Authors | Studies |
|---|---|
| Suryawanshi, SN | 2 |
| Pandey, S | 1 |
| Bhatt, BA | 1 |
| Gupta, S | 9 |
| Wang, MZ | 1 |
| Zhu, X | 2 |
| Srivastava, A | 2 |
| Liu, Q | 1 |
| Sweat, JM | 2 |
| Pandharkar, T | 2 |
| Stephens, CE | 1 |
| Riccio, E | 1 |
| Parman, T | 1 |
| Munde, M | 1 |
| Mandal, S | 1 |
| Madhubala, R | 1 |
| Tidwell, RR | 1 |
| Wilson, WD | 1 |
| Boykin, DW | 1 |
| Hall, JE | 1 |
| Kyle, DE | 2 |
| Werbovetz, KA | 2 |
| Bahar, M | 1 |
| Deng, Y | 1 |
| He, S | 1 |
| Drew, ME | 1 |
| Navarro-Vázquez, A | 1 |
| Anklin, C | 1 |
| Gil, RR | 1 |
| Doskotch, RW | 2 |
| Kinghorn, AD | 2 |
| Tiwari, A | 1 |
| Kumar, S | 1 |
| Mittal, M | 1 |
| Vishwakarma, P | 4 |
| Gopinath, VS | 1 |
| Pinjari, J | 1 |
| Dere, RT | 1 |
| Verma, A | 1 |
| Shivahare, R | 2 |
| Moger, M | 1 |
| Kumar Goud, PS | 1 |
| Ramanathan, V | 1 |
| Bose, P | 1 |
| Rao, MV | 1 |
| Puri, SK | 1 |
| Launay, D | 2 |
| Martin, D | 1 |
| Korthikunta, V | 1 |
| Singh, R | 1 |
| Tadigoppula, N | 1 |
| Adam, R | 1 |
| Bilbao-Ramos, P | 1 |
| López-Molina, S | 1 |
| Abarca, B | 1 |
| Ballesteros, R | 1 |
| González-Rosende, ME | 1 |
| Dea-Ayuela, MA | 1 |
| Alzuet-Piña, G | 1 |
| Giannini, G | 1 |
| Battistuzzi, G | 1 |
| Vignola, D | 1 |
| Naman, CB | 1 |
| Gupta, G | 1 |
| Varikuti, S | 1 |
| Chai, H | 1 |
| Satoskar, AR | 2 |
| Papadopoulou, MV | 1 |
| Bloomer, WD | 1 |
| Rosenzweig, HS | 1 |
| O'Shea, IP | 1 |
| Wilkinson, SR | 1 |
| Kaiser, M | 1 |
| Chatelain, E | 2 |
| Ioset, JR | 1 |
| Salado, IG | 1 |
| Baán, A | 1 |
| Verdeyen, T | 1 |
| Matheeussen, A | 1 |
| Caljon, G | 4 |
| Van der Veken, P | 1 |
| Kiekens, F | 1 |
| Maes, L | 8 |
| Augustyns, K | 1 |
| Upadhyay, A | 1 |
| Chandrakar, P | 2 |
| Parmar, N | 2 |
| Singh, SK | 1 |
| Rashid, M | 1 |
| Kushwaha, P | 1 |
| Wahajuddin, M | 1 |
| Sashidhara, KV | 1 |
| Kar, S | 2 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Thompson, AM | 1 |
| O'Connor, PD | 1 |
| Marshall, AJ | 1 |
| Yardley, V | 4 |
| Braillard, S | 2 |
| Wan, B | 1 |
| Franzblau, SG | 1 |
| Ma, Z | 1 |
| Cooper, CB | 1 |
| Denny, WA | 1 |
| Mowbray, CE | 1 |
| Glossop, PA | 1 |
| Whitlock, GA | 1 |
| Jacobs, RT | 1 |
| Speake, J | 1 |
| Pandi, B | 1 |
| Nare, B | 1 |
| Freund, Y | 1 |
| Wall, RJ | 1 |
| Carvalho, S | 1 |
| Bello, D | 1 |
| Van den Kerkhof, M | 3 |
| Gilbert, IH | 1 |
| Corpas-Lopez, V | 1 |
| Lukac, I | 1 |
| Patterson, S | 1 |
| Zuccotto, F | 1 |
| Wyllie, S | 1 |
| Park, SY | 1 |
| Kim, JH | 1 |
| Choi, JH | 1 |
| Lee, CJ | 1 |
| Lee, WJ | 1 |
| Park, S | 1 |
| Park, ZY | 1 |
| Baek, JH | 1 |
| Nam, JS | 1 |
| Carregal, VM | 1 |
| Lanza, JS | 1 |
| Souza, DM | 1 |
| Islam, A | 1 |
| Demicheli, C | 1 |
| Fujiwara, RT | 1 |
| Rivas, L | 1 |
| Frézard, F | 1 |
| Dar, MJ | 1 |
| Khalid, S | 1 |
| McElroy, CA | 1 |
| Khan, GM | 1 |
| Loreto, ES | 1 |
| Tondolo, JSM | 1 |
| de Jesus, FPK | 1 |
| Engelmann, AM | 1 |
| de Andrade, CM | 1 |
| Santurio, JM | 1 |
| Zanette, RA | 1 |
| Kommers, GD | 1 |
| Silva, TM | 1 |
| Alves, SH | 1 |
| Buechler, C | 1 |
| Aslanidis, C | 1 |
| Barakat, AM | 2 |
| Saafan, AE | 1 |
| Melek, ST | 1 |
| Behour, TS | 1 |
| Khairy, NM | 1 |
| Khairalla, AS | 1 |
| Ferreira, C | 1 |
| Mesquita, I | 1 |
| Barbosa, AM | 1 |
| Osório, NS | 1 |
| Torrado, E | 1 |
| Beauparlant, CJ | 1 |
| Droit, A | 1 |
| Cunha, C | 1 |
| Carvalho, A | 1 |
| Saha, B | 1 |
| Estaquier, J | 1 |
| Silvestre, R | 1 |
| Eberhardt, E | 4 |
| Hendrickx, R | 1 |
| Monnerat, S | 1 |
| Alves, F | 1 |
| Hendrickx, S | 4 |
| Eissa, MM | 5 |
| El-Azzouni, MZ | 4 |
| El-Khordagui, LK | 3 |
| Abdel Bary, A | 2 |
| El-Moslemany, RM | 3 |
| Abdel Salam, SA | 2 |
| Wijnant, GJ | 1 |
| Van Bocxlaer, K | 2 |
| Murdan, S | 2 |
| Croft, SL | 2 |
| Koch, G | 1 |
| Wermser, C | 1 |
| Acosta, IC | 1 |
| Kricks, L | 1 |
| Stengel, ST | 1 |
| Yepes, A | 1 |
| Lopez, D | 1 |
| Valdivieso, E | 1 |
| Mejías, F | 1 |
| Carrillo, E | 1 |
| Sánchez, C | 1 |
| Moreno, J | 1 |
| Álvarez-Velilla, R | 1 |
| Gutiérrez-Corbo, MDC | 1 |
| Punzón, C | 1 |
| Pérez-Pertejo, MY | 1 |
| Balaña-Fouce, R | 1 |
| Fresno, M | 1 |
| Reguera, RM | 1 |
| Neira, LF | 1 |
| Mantilla, JC | 1 |
| Escobar, P | 1 |
| Polat, ZA | 2 |
| Walochnik, J | 2 |
| Obwaller, A | 2 |
| Vural, A | 2 |
| Dursun, A | 1 |
| Arici, MK | 1 |
| Verhaar, AP | 1 |
| Wildenberg, ME | 1 |
| te Velde, AA | 1 |
| Meijer, SL | 1 |
| Vos, AC | 1 |
| Duijvestein, M | 1 |
| Peppelenbosch, MP | 1 |
| Hommes, DW | 1 |
| van den Brink, GR | 1 |
| Coelho, AC | 2 |
| Trinconi, CT | 2 |
| Costa, CH | 1 |
| Uliana, SR | 2 |
| Fortin, A | 2 |
| Caridha, DP | 1 |
| Leed, S | 1 |
| Ngundam, F | 1 |
| Sena, J | 1 |
| Bosschaerts, T | 2 |
| Parriott, S | 1 |
| Hickman, MR | 1 |
| Hudson, TH | 1 |
| Grogl, M | 1 |
| Santarem, AA | 1 |
| Greggianin, GF | 1 |
| Debastiani, RG | 1 |
| Ribeiro, JB | 1 |
| Polli, DA | 1 |
| Sampaio, RN | 1 |
| Paulussen, C | 1 |
| Boulet, G | 1 |
| Cos, P | 3 |
| Mondelaers, A | 3 |
| Delputte, P | 2 |
| Amer, EI | 2 |
| Younis, LK | 1 |
| de Morais-Teixeira, E | 1 |
| Aguiar, MG | 2 |
| Soares de Souza Lima, B | 1 |
| Ferreira, LA | 2 |
| Rabello, A | 1 |
| Yadav, PK | 1 |
| Reimão, JQ | 1 |
| Ramadan, AA | 1 |
| Beyers, J | 1 |
| Lachaud, L | 1 |
| Ratna, A | 1 |
| Arora, SK | 1 |
| Tiwari, B | 1 |
| Pahuja, R | 1 |
| Kumar, P | 1 |
| Rath, SK | 1 |
| Gupta, KC | 1 |
| Goyal, N | 1 |
| Manna, L | 1 |
| Vitale, F | 1 |
| Reale, S | 1 |
| Picillo, E | 1 |
| Neglia, G | 1 |
| Vescio, F | 1 |
| Gravino, AE | 1 |
| Serrano-Martín, X | 1 |
| Payares, G | 1 |
| De Lucca, M | 1 |
| Martinez, JC | 1 |
| Mendoza-León, A | 1 |
| Benaim, G | 1 |
| Silva, DL | 1 |
| Nunan, FA | 1 |
| Nunan, EA | 1 |
| Fernandes, AP | 1 |
| Bäumer, W | 1 |
| Wlaź, P | 1 |
| Jennings, G | 1 |
| Rundfeldt, C | 1 |
| Sane, SA | 2 |
| Shakya, N | 2 |
| Baddour, NM | 1 |
| Wargo, MJ | 1 |
| Gross, MJ | 1 |
| Rajamani, S | 1 |
| Allard, JL | 1 |
| Lundblad, LK | 1 |
| Allen, GB | 1 |
| Vasil, ML | 1 |
| Leclair, LW | 1 |
| Hogan, DA | 1 |
| Bajpai, P | 1 |
| Campos Vieira, N | 1 |
| Vacus, J | 1 |
| Fournet, A | 1 |
| Baudouin, R | 1 |
| Bories, C | 2 |
| Séon-Méniel, B | 1 |
| Figadère, B | 1 |
| Loiseau, PM | 2 |
| Gupta, R | 1 |
| Kushawaha, PK | 1 |
| Samant, M | 1 |
| Jaiswal, AK | 1 |
| Baharia, RK | 1 |
| Dube, A | 2 |
| Debache, K | 1 |
| Hemphill, A | 1 |
| Wege, AK | 1 |
| Florian, C | 1 |
| Ernst, W | 1 |
| Zimara, N | 1 |
| Schleicher, U | 1 |
| Hanses, F | 1 |
| Schmid, M | 1 |
| Ritter, U | 1 |
| Azizan, A | 1 |
| Vesely, B | 1 |
| Singh, N | 2 |
| Sundar, S | 1 |
| Papagiannaros, A | 1 |
| Demetzos, C | 1 |
| Widmer, F | 1 |
| Wright, LC | 1 |
| Obando, D | 1 |
| Handke, R | 1 |
| Ganendren, R | 1 |
| Ellis, DH | 1 |
| Sorrell, TC | 1 |
| Sindermann, H | 1 |
| Engel, J | 1 |
| Vasseneix, C | 1 |
| Gargala, G | 1 |
| François, A | 1 |
| Hellot, MF | 1 |
| Duclos, C | 1 |
| Muraine, M | 1 |
| Benichou, J | 1 |
| Ballet, JJ | 1 |
| Brasseur, G | 1 |
| Favennec, L | 1 |
| Iqbal, J | 1 |
| Bukhari, I | 1 |
| Jamshid, M | 1 |
| Bashir, S | 1 |
| Masoom Yasinzai, M | 1 |
| Anwar, M | 1 |
| Arndt, D | 1 |
| Zeisig, R | 1 |
| Fichtner, I | 1 |
| Teppke, AD | 1 |
| Fahr, A | 1 |
| Murray, HW | 1 |
| Eue, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for miltefosine and Disease Models, Animal
| Article | Year |
|---|---|
Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Prolif | 2020 |
Development of miltefosine as an oral treatment for leishmaniasis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Age | 2006 |
68 other studies available for miltefosine and Disease Models, Animal
| Article | Year |
|---|---|
Chemotherapy of leishmaniasis Part VI: synthesis and bioevaluation of some novel terpenyl S,N- and N,N-acetals.
Topics: Acetals; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Leishmania donovani; Lei | 2007 |
Novel arylimidamides for treatment of visceral leishmaniasis.
Topics: Amidines; Animals; Antiprotozoal Agents; Biological Availability; Cricetinae; Disease Models, Animal | 2010 |
Potent antiprotozoal activity of a novel semi-synthetic berberine derivative.
Topics: Animals; Antiprotozoal Agents; Berberine; Chlorocebus aethiops; Disease Models, Animal; Inhibitory C | 2011 |
Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Cell Survival; Chalcones; Cricetinae; Disease Model | 2013 |
Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cricetinae; Disease Models, Animal; Drug Design; Leishmani | 2013 |
Synthesis and biological evaluation of chalcones as potential antileishmanial agents.
Topics: Animals; Cell Line; Chalcones; Chlorocebus aethiops; Cricetinae; Disease Models, Animal; Dose-Respon | 2014 |
Triazolopyridyl ketones as a novel class of antileishmanial agents. DNA binding and BSA interaction.
Topics: Animals; Antiprotozoal Agents; Binding, Competitive; Cattle; Cell Line; Cell Survival; Disease Model | 2014 |
Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Topics: Animals; Antimalarials; Cell Line, Tumor; Dipeptides; Disease Models, Animal; Histone Deacetylase In | 2015 |
Northalrugosidine is a bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum with in vivo antileishmanial activity.
Topics: Alkaloids; Animals; Disease Models, Animal; Humans; Isoquinolines; Leishmania donovani; Leishmaniasi | 2015 |
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line; Chagas Disease; Disease Models, Animal; Leishmania donovani; Mice | 2015 |
Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Topics: Animals; Disease Models, Animal; Humans; Mice; Structure-Activity Relationship; Triazines; Tropolone | 2018 |
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Chemistry Techniques, Synthetic; Chlorocebus aethiops; Disease Models | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; | 2021 |
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Benzoxazoles; Boron Compounds; Cricetinae; Disease Models, Animal; Do | 2021 |
Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Me | 2021 |
Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Female; Leish | 2019 |
Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Topics: Administration, Cutaneous; Amphotericin B; Animals; Antiprotozoal Agents; Disease Models, Animal; Dr | 2020 |
Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits.
Topics: Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Disease Progression; Dose-Respon | 2020 |
Biological risk assessment of miltefosine in concomitant infection with opportunistic toxoplasmosis.
Topics: Animal Structures; Animals; Disease Models, Animal; Female; Immunologic Factors; Injections, Intrape | 2019 |
Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dietary Supplements; Disease Models, Animal; Female; Glutamine; Human | 2020 |
Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based Leishmania detection in blood as proxy for visceral burdens.
Topics: Animals; Cricetinae; Disease Models, Animal; DNA; DNA, Kinetoplast; Female; Humans; Indicators and R | 2020 |
Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Drug Compounding; Female; | 2020 |
Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Topics: Animals; Anthelmintics; Disease Models, Animal; Drug Carriers; Drug Combinations; Granuloma; Lipids; | 2020 |
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Chloroquine; Disease Models, Animal; Drug Combination | 2017 |
Attenuating Staphylococcus aureus Virulence by Targeting Flotillin Protein Scaffold Activity.
Topics: Animals; Bacterial Proteins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Endoribon | 2017 |
Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Survival; Disease Models, Animal; Drug Synergism | 2018 |
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Discovery; Female; Leishmania infantum; | 2019 |
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Biopsy; Disease Models, Animal; Drug Stabili | 2019 |
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Biguanides; Cell Line; Cell Pro | 2014 |
Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immun | 2013 |
In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania; | 2014 |
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania major; Leish | 2014 |
Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Evaluation, Precli | 2014 |
Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus fumigatus; Azoles; Disease Model | 2015 |
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishman | 2015 |
Could miltefosine be used as a therapy for toxoplasmosis?
Topics: Animals; Antiprotozoal Agents; Brain; Disease Models, Animal; Infectious Encephalitis; Liver; Mice; | 2015 |
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Sched | 2015 |
15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Cricetulus; Disease Models, Ani | 2016 |
Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Interactions; Drug | 2016 |
Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Repositioning; Granuloma; Liver; Mice; N | 2016 |
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania i | 2016 |
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Topics: Administration, Topical; Animals; Cells, Cultured; Disease Models, Animal; Drug Compounding; Female; | 2016 |
Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
Topics: Animals; Cricetinae; Disease Models, Animal; Female; Leishmania donovani; Leishmania infantum; Leish | 2016 |
Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites.
Topics: Animals; Antigens, Protozoan; Cricetinae; Disease Models, Animal; Leishmania; Leishmaniasis; Macroph | 2016 |
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Curcumin; Disea | 2017 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases | 2009 |
Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.
Topics: Amiodarone; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Synergism; Femal | 2009 |
Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Topics: Administration, Oral; Administration, Topical; Animals; Disease Models, Animal; Drug Therapy, Combin | 2009 |
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; | 2010 |
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; D | 2011 |
Miltefosine, a promising novel agent for schistosomiasis mansoni.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Liver; Male; Mice; Microscopy, Electron, Scan | 2011 |
Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.
Topics: Animals; Antifungal Agents; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Disease Models, Animal; H | 2011 |
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Disease Models, Animal; Drug Therapy, Combina | 2011 |
Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2012 |
Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Anim | 2011 |
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Cytokines; Dis | 2012 |
Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Chlorocebus aethiops; Coccidiosis; Disease Models, A | 2012 |
Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Humans; Immune Evasion; Leishmania major; Lei | 2012 |
Real-time PCR to quantify Leishmania donovani in hamsters.
Topics: Amidines; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; DNA, Kinetoplast; Dose- | 2013 |
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line; Cricetinae; Dis | 2005 |
Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Topics: Amines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug | 2005 |
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.
Topics: Acyltransferases; Animals; Antifungal Agents; Cryptococcosis; Disease Models, Animal; Enzyme Inhibit | 2006 |
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2006 |
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial.
Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoa | 2006 |
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disea | 1999 |
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania donovani; Le | 2000 |
Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Humans | 2001 |